How an Unproven Alzheimer’s Drug Got ApprovedThough some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen’s Aduhelm, or aducanumab.http://rss.nytimes.com/services/xml/rss/nyt/Technology.xmlNYT > Technologyhttps://static01.nyt.com/images/misc/NYT_logo_rss_250x40.pngTechnology124Pam Belluck, Sheila Kaplan and Rebecca Robbins
Powered by WPeMatico